502 related articles for article (PubMed ID: 31853314)
1. miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC.
Shen X; Lei J; Du L
Exp Ther Med; 2020 Jan; 19(1):375-383. PubMed ID: 31853314
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
3. miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression.
Hou X; Niu Z; Liu L; Guo Q; Li H; Yang X; Zhang X
Oncol Lett; 2019 Jan; 17(1):990-998. PubMed ID: 30655858
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis.
Xu W; Song C; Wang X; Li Y; Bai X; Liang X; Wu J; Liu J
Aging (Albany NY); 2021 Jan; 13(1):228-240. PubMed ID: 33472170
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of microRNA-620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD.
Wu C; Zhao A; Tan T; Wang Y; Shen Z
Exp Ther Med; 2019 Jul; 18(1):550-558. PubMed ID: 31258693
[TBL] [Abstract][Full Text] [Related]
7. MiR-153-5p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Paclitaxel by Inducing G2M Phase Arrest.
Wang Y; Wu N; Zhang J; Wang H; Men X
Onco Targets Ther; 2020; 13():4089-4097. PubMed ID: 32494162
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition.
Guan X; Gu S; Yuan M; Zheng X; Wu J
Oncol Lett; 2019 Dec; 18(6):5986-5994. PubMed ID: 31788073
[TBL] [Abstract][Full Text] [Related]
9. The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer.
Dastmalchi N; Azarbarzin S; Safaralizadeh R; Khojasteh SMB; Shadbad MA; Amini M; Baghbanzadeh A; Asl ER; Baghbani E; Lotfinejad P; Baradaran B
Med Oncol; 2021 Nov; 39(1):9. PubMed ID: 34761351
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of miR-483-5p improves the proliferation, invasion and inflammatory response of triple-negative breast cancer cells by targeting SOCS3.
Ren J; Xu G; Sun H; Lin T; Xu S; Zhao Y
Exp Ther Med; 2021 Oct; 22(4):1047. PubMed ID: 34434261
[TBL] [Abstract][Full Text] [Related]
11. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
[TBL] [Abstract][Full Text] [Related]
12. miR-497 inhibits proliferation and invasion in triple-negative breast cancer cells via YAP1.
Li Y; Hua K; Jin J; Fang L
Oncol Lett; 2021 Aug; 22(2):580. PubMed ID: 34122631
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.
Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H
Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999
[TBL] [Abstract][Full Text] [Related]
14. Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.
Li S; Li Q; Lü J; Zhao Q; Li D; Shen L; Wang Z; Liu J; Xie D; Cho WC; Xu S; Yu Z
Front Genet; 2019; 10():1278. PubMed ID: 32010177
[TBL] [Abstract][Full Text] [Related]
15. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].
Ma T; Zhang J; Wu J; Tang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-362-5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein.
Wei X; Gao M; Ahmed Y; Gao M; Liu W; Zhang Y; Xie X; Zhao Q; Wang H; Gu K
Oncol Lett; 2019 Aug; 18(2):1607-1616. PubMed ID: 31423228
[TBL] [Abstract][Full Text] [Related]
18. A thiosemicarbazone derivative induces triple negative breast cancer cell apoptosis: possible role of miRNA-125a-5p and miRNA-181a-5p.
El Majzoub R; Fayyad-Kazan M; Nasr El Dine A; Makki R; Hamade E; Grée R; Hachem A; Talhouk R; Fayyad-Kazan H; Badran B
Genes Genomics; 2019 Dec; 41(12):1431-1443. PubMed ID: 31541355
[TBL] [Abstract][Full Text] [Related]
19. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
[TBL] [Abstract][Full Text] [Related]
20. TNFAIP8 Promotes Cisplatin Chemoresistance in Triple-Negative Breast Cancer by Repressing p53-Mediated miR-205-5p Expression.
Ma HY; Li Y; Yin HZ; Yin H; Qu YY; Xu QY
Mol Ther Nucleic Acids; 2020 Dec; 22():640-656. PubMed ID: 33230463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
